BROADCASTS.com

In his weekly clinical update, Dr. Griffin\xa0discusses the\xa0U.S. Food and Drug Administration approving Arexvy: the first respiratory syncytial virus (RSV) vaccine approved for use in the United State,\xa0association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market,\xa0researchers disagree over how bad it is to be reinfected and whether COVID-19 can cause lasting changes to the immune system,\xa0virtual care and emergency department use during the COVID-19 pandemic among patients of family physicians in Canada,\xa0vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers than placebo,\xa0NVX-CoV2373 vaccine efficacy against hospitalization,\xa0comparative effectiveness of the SARS-COV-2 vaccines during Delta dominance, assessment of gender-specific COVID-19 case fatality risk per malignant neoplasm type,\xa0clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir among patients living in nursing homes,\xa0timing of intubation and ICU mortality in COVID-19 patients,\xa0real-life experience with Remdesivir for treatment of COVID-19 among older adults, and how\xa0long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.

Become a\xa0patron\xa0of\xa0TWiV!

• FDA\xa0approves Arexvy, the first RSV vaccine approved in the US (FDA)
• Association between\xa0SARS-CoV-2 and content of samples\xa0from the Huanan Seafood Market (bioRxiv)
• Researchers disagree over how bad it is to be\xa0reinfected with COVID-19\xa0and lasting changes to the immune system (Nature)
• Virtual care and emergency department\xa0use during the COVID-19 Pandemic among patients of family physicians (JAMA)
• Vaccination with BCG-Denmark did not result in a\xa0lower risk of COVID-19\xa0among health care workers (NEJM)
• NVX-CoV2373 vaccine efficacy\xa0against hospitalization (Vaccine)
• Comparative effectiveness of the\xa0SARS-COV-2 vaccines\xa0during Delta (Cell)
• Assessment\xa0of gender-specific COVID-19 case fatality risk (JAMA)
• Clinical outcomes following\xa0treatment for COVID-19\xa0with Nirmatrelvir/Ritonavir and Molnupiravir (JAMA)
• Timing\xa0of intubation and ICU mortality in COVID-19 patients (BMC)
• Real-life experience with Remdesivir for\xa0treatment of COVID-19\xa0(JAC)
• Long COVID\xa0brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA (Frontiers)
• Contribute to our\xa0FIMRC fundraiser at PWB
• Letters read\xa0on TWiV 1004
• Timestamps by\xa0Jolene. Thanks!

Intro music is by\xa0Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv